key: cord-0264442-955uf3cl authors: van Dorp, Lucy; Nimmo, Camus; Ortiz, Arturo Torres; Pang, Juanita; Acman, Mislav; Tan, Cedric C.S.; Millard, James; Padayatchi, Nesri; Grant, Alison; O’Donnell, Max; Pym, Alex; Brynildsrud, Ola B; Eldholm, Vegard; Grandjean, Louis; Didelot, Xavier; Balloux, François title: Detection of a bedaquiline / clofazimine resistance reservoir in Mycobacterium tuberculosis predating the antibiotic era date: 2020-10-07 journal: bioRxiv DOI: 10.1101/2020.10.06.328799 sha: f447475d6f4b4ab2a7c1be8e7cfd7b31fedcb0c8 doc_id: 264442 cord_uid: 955uf3cl Drug resistance in tuberculosis (TB) poses a major ongoing challenge to public health. The recent inclusion of bedaquiline into TB drug regimens has improved treatment outcomes, but this advance is threatened by the emergence of strains of Mycobacterium tuberculosis (Mtb) resistant to bedaquiline. Clinical bedaquiline resistance is most frequently conferred by resistance-associated variants (RAVs) in the Rv0678 gene which can also confer cross-resistance to clofazimine, another TB drug. We compiled a dataset of 3,682 Mtb genomes, including 223 carrying Rv0678 bedaquiline RAVs. We identified at least 15 cases where RAVs were present in the genomes of strains collected prior to the use of bedaquiline in TB treatment regimes. Phylogenetic analyses point to multiple emergence events and in some cases widespread circulation of RAVs in Rv0678, often prior to the introduction of bedaquiline or clofazimine. Strikingly, this included three cases predating the antibiotic era. The presence of a pre-existing reservoir of bedaquiline-resistant Mtb strains necessitates the urgent implementation of rapid drug susceptibility testing and individualised regimen selection to safeguard the use of bedaquiline in TB care and control. Drug-resistant tuberculosis (DR-TB) currently accounts for 500,000 of the 10 million new tuberculosis (TB) cases reported annually 1 , with incidence expected to rise substantially due to the ongoing Covid-19 pandemic 2 . Treatment outcomes for multidrug-resistant TB (MDR-TB) resistant to at least rifampicin and isoniazid have historically been poor, with treatment success rates of only 50-60% in routine programmatic settings 1, 3 . The discovery of bedaquiline, a diarylquinoline antimycobacterial active against ATP synthase, which is highly effective against Mycobacterium tuberculosis (Mtb) 4 Cohort studies of patients treated with bedaquiline-containing regimens against MDR-TB report success rates of 70-80% 7, 8 . Similar results have been achieved for extensively drug-resistant TB (XDR-TB, defined by additional resistance to fluoroquinolones and injectables), where treatment outcomes without bedaquiline are even worse 9, 10 . In light of these promising results, the World Health Organization (WHO) now recommends that bedaquiline be included in all MDR-TB regimens 11 . In addition, bedaquiline is positioned as a key drug in multiple phase III clinical trials for drug-susceptible TB (SimpliciTB, ClinicalTrials.gov NCT03338621), MDR-TB (STREAM2, ClinicalTrials.gov NCT02409290) and XDR-TB (ZENIX-TB, ClinicalTrials.gov NCT03086486). Unlike other major drug-resistant bacteria, Mtb reproduces strictly clonally and systematically acquires resistance by chromosomal mutations rather than via horizontal gene transfer or recombination 12 . Phylogenetic reconstructions based on whole genome sequencing can therefore accurately infer the time of emergence and subsequent spread of Mtb resistance-associated variants (RAVs). Phylogenetic studies have demonstrated that there are often multiple Mtb lineages introduced into distinct geographical regions, with repeated independent drug resistance emergence events occurring locally [13] [14] [15] [16] . Mtb has demonstrated the ability to acquire resistance to every drug used against it until now. Resistance has been reported to occur soon after the introduction of a novel TB drug 17, 18 . For example, mutations conferring resistance to isoniazid -one of the first antimycobacterials -tend to have emerged prior to resistance to rifampicin, the other major first-line drug. These also predate resistance mutations to second-line drugs, so termed because they are used clinically to treat patients infected with strains already resistant to first-line drugs. This was observed, for example, in KwaZulu-Natal, South Africa, where resistance-associated mutations accumulated over decades prior to their identification, leading to the largest reported outbreak of extensively drug-resistant TB (XDR-TB) 18 . Mutations conferring resistance to bedaquiline were first selected in vitro, and were located in the atpE gene encoding the target F1F0 ATP synthase, the target of bedaquiline 19 . Subsequently, resistanceconferring mutations have been found in pepQ in a murine model and potentially in a small number of patients 20 . However, the vast majority of resistance observed in clinical isolates has been identified in the context of resistance-associated variants (RAVs) in the Rv0678 gene, a negative repressor of expression of the MmpL5 efflux pump. Loss of function of Rv0678 leads to pump overexpression 21 and increased minimum inhibitory concentrations (MIC) to bedaquiline, as well as to the recently repurposed antimycobacterial clofazimine and the azole class of antifungal drugs (which also have antimycobacterial activity) 22 . A diverse range of single nucleotide variants (SNVs) and frameshift Rv0678 mutations have been associated with resistance to bedaquiline, and are often present as heteroresistant alleles in patients [23] [24] [25] [26] [27] [28] [29] [30] . In contrast to most other RAVs in Mtb, which often cause many-fold increases in MIC and clear-cut resistance, Rv0678 variants may be associated with normal MICs or subtle increases in bedaquiline MIC, although they may still be clinically important. These increases may not cross the current WHO critical concentrations used to classify resistant versus susceptible strains (0.25µg/mL on Middlebrook 7H11 agar, or 1µg/mL in Mycobacteria Growth Indicator Tube [MGIT] liquid media). Bedaquiline has a long terminal half-life of up to 5.5 months 6 , leading to the possibility of subtherapeutic concentrations, where adherence is suboptimal or treatment is interrupted, which could act as a further driver of resistance. Bedaquiline and clofazimine cross-resistance has now been reported across three continents following the rapid expansion in usage of both drugs 24, 29, 31, 32 , and is associated with poor adherence to therapy and inadequate regimens. However, baseline isolates in 8/347 (2.3%) patients from phase IIb bedaquiline trials demonstrated Rv0678 RAVs and high bedaquiline MICs in the absence of prior documented use of bedaquiline or clofazimine 33 , suggesting that bedaquiline RAVs could pre-exist in many settings where bedaquiline will be used. While there are isolated clinical reports from multiple geographical regions, the global situation regarding bedaquiline resistance emergence and spread has not yet been investigated. In this study, we characterised and dated the emergence of bedaquiline RAVs in the two global Mtb lineage 2 (L2) and lineage 4 (L4) lineages, which include the majority of drug resistance strains 17 . Phylogenetic analyses of two datasets comprising 1,514 Mtb L2 and 2,168 L4 whole genome sequences revealed the emergence and spread of multiple Rv0678 RAVs prior to the use of bedaquiline or clofazimine, with some mutations having been in circulation already before the antibiotic era. This preexisting reservoir of bedaquiline/clofazimine-resistant Mtb strains suggests Rv0678 RAVs exert a relatively low fitness cost which could be rapidly selected for as bedaquiline and clofazimine are more widely used in the treatment of TB. To investigate the global distribution of Mtb isolates with variants in Rv0678, we curated two large datasets of whole genomes from the two dominant global lineages L2 and L4. Both datasets were selectively enriched for samples with variants in Rv0678 (see Methods) and those with accompanying Using the same approach for the L4 dataset we estimated a clock rate of 7.1x10 -8 (6.2x10 -8 -7.9x10 -8 ) substitutions per site per year resulting in an estimated tMRCA of 853CE (685CE -967CE) ( Figure 2 ). We observed a slightly higher, yet statistically not significant, clock rate in L2 compared to L4 (Supplementary Table S3) , with all estimated substitution rates falling largely in line with previously published estimates 41 . Since atpE and pepQ bedaquiline RAVs are found at very low prevalence, we focused on characterising the full mutational spectrum of Rv068 across both lineages. In total we identified the presence of non- Of the 198 L2 isolates identified as carrying variants in Rv0678, 18 samples had more than one variant in the same gene (10%). In L4, 14 samples (6%) were observed with more than one variant co-occurring in the Rv0678 gene. We identified a significant relationship between the presence of Rv0678 variants and drug resistance status in both the L2 and L4 datasets (Supplementary Figure S8-S9) , though in both cases we identified otherwise fully phenotypically susceptible isolates carrying Rv0678 RAVs (12 L2, 25 L4). We identified one L2 isolate (ERR2677436 sampled in Germany in 2016) which already had two Rv0678 RAVs at low allele frequency -Val7fs (11%) and Val20Phe (20%) -and also contained two low frequency atpE RAVs: Glu61Asp (3.2%) and Alal63Pro (3.7%). We also identified three isolates obtained in 2007-08 from separate but neighbouring Chinese provinces carrying the Rv1979c Val52Gly RAV, which has been reported to be associated with clofazimine resistance in a study from China 24 but was associated with a normal MIC in another 42 . Furthermore, several frameshift and premature stop mutations in pepQ have been previously associated with bedaquiline and clofazimine resistance. In this dataset, we identified 18 frameshift mutations in pepQ across 11 patients, one of which also had a Rv0678 frameshift mutation. In one isolate the pepQ frameshift occurred at the Arg271 position previously reported to be associated with bedaquiline resistance 20 . Across our datasets we identified 62 genomes with nonsynonymous Rv0678 variants of unknown phenotypic effect (12 L2, 50 L4), corresponding to 23 unique mutations or combinations of mutations. A gradient-boosted tree classifier was trained and optimised to determine if the amino acid properties of Rv0678 mutations associated to known bedaquiline resistance phenotypes can be used to predict the resistance status of mutations with no available phenotypic information. The optimised model provided an area under the precision-recall curve (AUPRC) of 0.805 (Supplementary Table S6 ), suggesting that the physiochemical properties of mutations can be used to successfully differentiate between resistance and susceptibility phenotypes (Supplementary Table S7 ). The features of the models were then interpreted using SHAP values (see Methods). Via this approach, we found that 5' end mutations, mutations in the DNA binding domain and polar and positively charged residues are associated with resistance. Conversely, mutations in the dimerisation domains, transitions from negatively to positively charged residues, and mutations involving hydrophobic wild type or variant residues are associated with susceptibility (Supplementary Figure S10) . To estimate the age of the emergence of different Rv0678 non-synonymous variants, we identified all nodes in the global time calibrated phylogenies delineating clades of isolates carrying a particular Our work establishes that the emergence of variants in Rv0678, including RAVs, is not solely driven by the use of bedaquiline and clofazimine or azoles (which have also been proposed as a further potential selective force) 22 Prediction of phenotypic bedaquiline resistance from genomic data is further complicated by the existence of hyper-susceptibility variants. For example, the C-11A variant located in the promoter of Rv0678, which appears to increase susceptibly to bedaquiline 33 Bedaquiline resistance can also be conferred by other RAVs including in pepQ (bedaquiline and clofazimine), atpE (bedaquiline only) 44 and Rv1979c (clofazimine only). We only found atpE RAVs at low allele frequency in one patient who also had Rv0678 variants (sample accession ERR2677436), which is in line with other evidence suggesting they rarely occur in clinical isolates, likely due to a high fitness cost. Likewise, we only identified Rv1979c RAVs in three patients in China, although there were other variants in Rv1979c for which ability to cause phenotypic resistance has not been previously assessed. Frameshift pepQ mutations that are potentially causative of resistance were identified in 11 patients, in keeping with its possible role as an additional rare resistance mechanism. Our findings are of high clinical relevance as the presence of Rv0678 variants during therapy in clinical strains has been associated with substantially worse outcomes in patients treated with drug regimens including bedaquiline 31 In this study we curated large representative datasets of Mtb whole genome sequences encompassing the global genetic and geographic distribution of lineages 2 (L2) and L4 (Figure 1, Supplementary Tables S1-S2 Original fastq files for all included sequences were downloaded and paired reads mapped to the H37Rv reference genome with bwa mem v0.7.17 61 . Mapped reads were sorted and de-duplicated using Picard Tools v2.20 followed by indel realignment with GATK v3.8 62 . Alignment quality and coverage was recorded with Qualimap v2.21 63 . Variant calling was performed using bcftools v1.9, based on reads mapping with a minimum mapping quality of 20, base quality of 20, no evidence of strand or position bias, a minimum coverage depth of 10 reads, and a minimum of four reads supporting the alternate allele, with at least two of them on each strand. Moreover, SNPs that were less than 2bp apart of an indel were excluded from the analysis. Similarly, only indels 3bp apart of other indels were kept. All sites with insufficient coverage to identify a site as variant or reference were excluded (marked as 'N'), as were those in or within 100 bases of PE/PPE genes, or in insertion sequences or phages. SNPs present in the alignment with at least 90% frequency were used to generate a pseudoalignment of equal length to the H37Rv reference using a custom Python script for use in phylogenetic analysis. Samples with more than 10% of the alignment represented by ambiguous bases were excluded. Those positions with more than 10% of ambiguous bases across all the samples were also removed. In order to avoid bias on the tree structure, positions known to be associated with drug resistance were not included. A more permissive variant calling pipeline was used to identify Rv0678 variants, as they are often present at <100% frequency with a high incidence of frameshift mutations. Here we instead employed FreeBayes v1.2 64 to call all variants present in the Rv0678 gene (or up to 100 bases upstream) that were present at ³5% frequency (alternate allele fraction -F 0.05) and supported by at least four reads including one on each strand. All raw fastq files were screened using the rapid resistance profiling tool TBProfiler 39,65 against a curated whole genome drug resistance mutations library. This allowed rapid assignment of polymorphisms associated with resistance to different antimycobacterial drugs and categorisation of MDR and XDR Mtb status (Supplementary Figure S2, Supplementary Figures S5-S9) . The diverse range of Rv0678 variants and paucity of widespread MIC testing means that there are limited data from which to infer the phenotypic consequences of identified Rv0678 variants. The Table S4 ). We were able to categorise 29/85 (34.1%) of the different non-synonymous and promoter mutations identified. Supplementary Table S7 . The alignments for phylogenetic inference were masked for the Rv0678 region using bedtools v2. 25 for the number of invariant sites using the ascertainment flag (ASC_STAM) and specifying a minimum branch length of 1x10 -9 reporting 12 decimal places (--precision 12). To test whether the resulting phylogenies can be time-calibrated we first dropped the outgroups from the phylogeny and rescaled the trees so that branches were measured in unit of substitutions per genome. We then computed a linear regression between root-to-tip distance and the time of sample collection using BactDating 72 , which additionally assesses the significance of the regression based on 10,000 date randomisations. We obtained a significant temporal correlation for both the L2 and L4 phylogenies, Figure S4) . BEAST2 v2.6.0 74 was run on both subsampled SNP alignments allowing for model averaging over possible choices of substitution models 75 . All models were run with either a relaxed or a strict prior on the evolutionary clock rate for three possible coalescent demographic models: exponential, constant and skyline. To speed up the convergence, the prior on the evolutionary clock rate was given as a uniform distribution (limits 0 to 10) with a starting value set to 10 -7 . In each case, the MCMC chain was run for 500,000,000 iterations, with the first 10% discarded as burn-in and sampling trees every 10,000 chains. (Figure 2) . The resulting phylogenetic trees were visualised and annotated for place of geographic sampling and Rv0678 variant status using ggtree v1.14.6 77 . All nonsynonymous mutations in Rv0678 were considered, with the phenotypic status assigned in Supplementary Table S4 . For the purpose of this analysis, and to be conservative, 'unknown' variants classified using XGBoost were still considered 'unknown'. Clades carrying shared variants in Rv0678 were identified and the age of the node (point estimates and 95% HPDs) extracted from the time-stamped phylogeny using the R package Ape v5.3 78 . For isolated samples (single emergences) exhibiting variants in Rv0678, the time of sample collection was extracted together with the date associated with the upper bound on the age of the next closest node of the tree (Figure 3, Supplementary Figures S11-S12) . For the oldest bedaquiline resistance clade, which comprised Ile67fs carriers predominately from Peru, Bayesian skyline analysis was implemented through the skylineplot analysis functionality available in Ape v5.3 78 . Raw sequence data and full metadata for all newly generated isolates are available on NCBI Sequencing Read Archive under BioProject ID: XXXXX. LvD, CN and FB conceived and designed the study. JM, NP, AG, MO, AP, OBB, VE and LG provided sequence data. ATO, JP, MA, CCST and XD performed and advised on computational analyses. LvD, CN and FB wrote the manuscript with input from all co-authors. All authors read and approved the final manuscript. Figures 11-12 and Supplementary Table S8. Tuberculosis and HIV responses threatened by COVID-19 Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (80-. ) Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline Sirturo (bedaquiline) product insert Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR-and XDR-TB: A multicentre study Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa High treatment success rate for multidrug-resistant and extensively drugresistant tuberculosis using a bedaquiline-containing treatment regimen World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment Antimicrobial Resistance in Mycobacterium Tuberculosis: The Odd One Out Global expansion of Mycobacterium tuberculosis lineage 4 shaped by colonial migration and local adaptation Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage Multiple introductions of Mycobacterium tuberculosis Lineage 2-Beijing into Africa over centuries Population-level emergence of bedaquiline and clofazimine resistanceassociated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis Acquired resistance of Mycobacterium tuberculosis to bedaquiline Cross-resistance between clofazimine and bedaquiline through upregulation of mmpl5 in mycobacterium tuberculosis Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis: To the editor Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis Examination of bedaquiline-and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan Emergence of Low-level Delamanid and Bedaquiline Resistance during Extremely Drug-resistant Tuberculosis Treatment Acquisition of bedaquiline resistance by extensively drug resistant Mycobacterium tuberculosis strain of Central Asian Outbreak clade Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline Eighteenth-century genomes show that mixed infections were common at time of peak tuberculosis in Europe Dynamics of within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment Lineage specific histories of Mycobacterium tuberculosis dispersal in Africa and Eurasia Global expansion of Mycobacterium tuberculosis lineage 4 shaped by colonial migration and local adaptation Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs BEAST 2.5: An advanced software platform for Bayesian evolutionary analysis The molecular clock of Mycobacterium tuberculosis Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance World Health Organization. Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB Reduced susceptibility of Mycobacterium tuberculosis to bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis A robust SNP barcode for typing Mycobacterium tuberculosis complex strains Identifying mixed Mycobacterium tuberculosis infections from whole genome sequence data Ultrafast search of all deposited bacterial and viral genomic data Southern East Asian origin and coexpansion of Mycobacterium tuberculosis Beijing family with Han Chinese Tuberculosis outbreak in an educational institution in Norway Whole genome sequencing Mycobacterium tuberculosis directly from sputum identifies more genetic diversity than sequencing from culture Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study Molecular epidemiological interpretation of the epidemic of extensively drug-resistant tuberculosis in South Africa Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence area Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study Convergent evolution and topologically disruptive polymorphisms among multidrug-resistant tuberculosis in Peru Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis High prevalence of bedaquiline resistance in treatment-naive tuberculosis patients and verapamil effectiveness Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM From fastQ data to high-confidence variant calls: The genome analysis toolkit best practices pipeline Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data Haplotype-based variant detection from short-read sequencing Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences XGBoost: A scalable tree boosting system Surface and inside volumes in globular proteins The Precision-Recall Plot Is More Informative than the ROC Plot When Evaluating Binary Classifiers on Imbalanced Datasets Predicting the functional effect of amino acid substitutions and indels SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments RAxML-NG: a fast, scalable and user-friendly tool for maximum likelihood phylogenetic inference Bayesian inference of ancestral dates on bacterial phylogenetic trees Treemmer: a tool to reduce large phylogenetic datasets with minimal loss of diversity BEAST: Bayesian evolutionary analysis by sampling trees Bayesian phylogenetic site model averaging and model comparison Improving the Accuracy of Demographic and Molecular Clock Model Comparison While Accommodating Phylogenetic Uncertainty ggtree : an r package for visualization and annotation of phylogenetic trees with their covariates and other associated data ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R The authors declare no competing financial interests. AP is currently employed by Janssen. Dr Pym's involvement with the research described herein precedes his employment at Janssen.